Procter & Gamble Hygiene and Health Care Limited
PGHH · NSE · Consumer Defensive
With a 20% margin of safety, our buy-below price is ₹4,449.8.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%114.9%
- ✓Low debt (D/E < 0.5)0.00x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-5%
- ✕Earnings growing-2%
- ✓Net margin ≥ 10%20.0%
- ✕Current ratio > 1.51.22
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 19.59
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (114.9%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (20.0%).
- •Financially solid — Altman Z 19.59.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Well off its 52-week high — possible mean-reversion.
Threats
- •Earnings contracting year on year.
- •Trades ~39% above our estimated fair value.
About Procter & Gamble Hygiene and Health Care Limited
Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast-moving consumer goods in the feminine care and healthcare businesses in India and internationally. It operates through Health care Products and Hygiene Products segments. The company offers health care products, including ointments and creams, cough drops, and tablets; and hygiene products, such as feminine hygiene and other skin care hygiene products, as well as feminine care pads
More in Consumer Defensive
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.